Facts on Drugs Used in Chemotherapy
Active substance: Cetuximab
Manufacturer: Bristol-Myers Squibb and ImClone
Extract from the prescribing information:
"Serious infusion reactions occurred with the administration of Erbitux in approximately 3% of patients in clinical trials, with fatal outcome reported in less than 1 in 1000."
"Cardiopulmonary arrest and/or sudden death occurred in 2% of 208 patients with squamous cell carcinoma of the head and neck treated with radiation therapy and Erbitux."
The above has been extracted from the Erbitux prescribing information on the Bristol-Myers Squibb webpages.